Portfolio overview

Oblique Therapeutics currently has six development programs in its pipeline: five are FTABS™ antibodies obtained with Abiprot™ within pain, advanced cancer and diabetes with a sixth program being a small molecule anticancer agent. Of these, three programs are developed in collaboration with leading pharmaceutical companies in their respective fields.